Celsion

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events

Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program

Independent Data Monitoring Committee is Expected to Meet in July 2020     to Evaluate Overall Survival Data

Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2019 Results - Earnings Call Transcript

Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population

Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm

Enters 2020 with a Strong Balance Sheet and  an Advancing Clinical Pipeline

Celsion Corporation Reports 2019 Financial Results and Provides Business Update

Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe

Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency

 R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only

Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer

LAWRENCEVILLE, N.J., March  03, 2020  (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued the following letter to stockholders.

Celsion CEO Issues Letter to Stockholders

LAWRENCEVILLE, NJ, Feb.  28, 2020  (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares of the Company’s common stock, par value $0.01 per share, pursuant to a registered direct offering. The Company has also agreed to issue to such investors, in a concurrent private placement, warrants to purchase 2,971,428 shares of the Company’s common stock. The warrants will be exercisable on the six-month anniversary of the issuance date, will expire on the five-year anniversary of the initial exercise date and have an exercise price of $1.15 per share. The gross proceeds of the offering will be approximately $4.8 million before deducting placement agent fees and other estimated offering expenses.

Celsion Corporation Prices $4.8 Million Registered Direct Offering

 Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy

Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m²  in 15 Randomized Patients with Advanced Ovarian Cancer

Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020

Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference

LAWRENCEVILLE, N.J., Dec.  18, 2019  (GLOBE NEWSWIRE) --   Celsion Corporation   (NASDAQ: C LSN ), an oncology drug development company, announces the signing of a memorandum of understanding (MOU) with officials from the Hangzhou Yuhang Economic Development Area to establish a subsidiary in the Yuhang District of Hangzhou, the capital of China’s Zhejiang Province. The Area, also known as the Qianjing Economic Development Area, is located in China’s biotech hub, where the Chinese government has made the development of advanced medical technologies that address unmet patient needs a high priority.

Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia

  Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share

Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Celsion Corporation (CLSN) CEO Michael Tardugno on Q3 2019 Results - Earnings Call Transcript

LAWRENCEVILLE, N.J, Nov.  14, 2019  (GLOBE NEWSWIRE) --  Celsion Corporation  (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the three-month and nine-month periods ended September 30, 2019 and provided an update on its development programs for ThermoDox® and GEN-1.

Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging

Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials

Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer

LAWRENCEVILLE, N.J. , Nov.  04, 2019  (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: C LSN ), an oncology drug development company, today announced that the independent Data Monitoring Committee (iDMC) has unanimously recommended the OPTIMA Study continue according to protocol. The recommendation was based on a review of blinded safety and data integrity from 556 patients enrolled in the Company’s multinational, double-blind, placebo-controlled pivotal Phase III study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer (the OPTIMA Study).

Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox®  in Primary Liver Cancer

LAWRENCEVILLE, N.J., Sept.  30, 2019  (GLOBE NEWSWIRE) --   Celsion Corporation    (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019 at 9:00 a.m. Eastern time. Management’s participation will take the form of a “Fireside Chat” and will primarily focus on the Company’s development program for GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. The conference is being held at the Westin New York Grand Central Hotel in New York City from October 7 - 8.

Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

LAWRENCEVILLE, N.J., Sept.  23, 2019  (GLOBE NEWSWIRE) --   Celsion Corporation    (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the recent 13th Annual Conference of the International Liver Cancer Association (ILCA). Other sponsors included Bayer Healthcare Pharmaceuticals, Inc. and Exelixis, Inc., both of whom provide therapeutics for the treatment of advanced HCC. The program, titled “Master Class & Tumor Board: Composing Personalized HCC Treatment Strategies, Insights on Harmonizing Patient Care with a Multidisciplinary Ensemble,” was held on September 20 in Chicago, and featured four speakers. The symposium’s timing verges on the upcoming meeting of the Data Monitoring Committee’s review of the first interim data for the Company’s Phase III OPTIMA Study of its lead drug candidate, ThermoDox®, to treat HCC.

Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference

Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2019 Results - Earnings Call Transcript

Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Celsion (CLSN) Report Negative Q2 Earnings? What You Should Know

Celsion therapy ThermoDox failed in a large study in liver cancer in 2013.

Celsion Approaches Drug Trial Binary

Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2019 Results - Earnings Call Transcript

Is  (CLSN) Outperforming Other Medical Stocks This Year?

News for Celsion Stock (CLSN)